[Treatment of severe forms of sickle cell anemia with bone marrow allograft: French experience (15 cases). SFGM]. 1993

F Bernaudin, and G Souillet, and J P Vannier, and E Plouvier, and S Lemerle, and G Michel, and P Bordigoni, and P Lutz, and J P Vernant
Unités de Greffe, Hôpital Henri Mondor, Créteil, France.

Fifteen S/S children with severe SCD were transplanted with marrow from HLA identical siblings. All developed frequent (> 3/y) vaso-occlusive crises (VOC) associated with recurrent acute chest syndrome episodes (n = 10), osteitis (n = 3), osteonecrosis (n = 3), strokes (n = 3) or frequent massive deglobulisation (n = 2). Two children undergone splenectomy, two were chelated and two had an erythroid allo-immunization. Ethnic origins were from various countries in Africa (n = 11), North-Africa (n = 3) or West Indies (n = 1). At BMT, they were 2y 3m to 14y 9m old (mean: 8y 7m). Donors were AS (n = 11) or AA (n = 4). At first, various conditioning regimens were used consisting of busulfan (BU) plus Cyclophosphamide (CY) at different doses: CY:200 mg/kg (n = 13) or 260 mg/kg (n = 2); BU: 14 mg/kg (n = 1), 16 mg/kg (n = 9), > 16 mg/kg (n = 5); one patient received also TLI and the last two anti-thymoglobulin (ATG): 20 mg/kg. GVHD prophylaxis was CSA alone (n = 4) or CSA plus short-term MTX (n = 11). Median follow-up is 28 months (5 m to 53 m). All patients had an engraftment (d12 to d32) with a stable total chimerism in 10/14 patients. In the 4 others, partial chimerism was observed: one patient had a early and progressive rejection of his graft but is doing very well (35 m follow-up) without any manifestation of SCD, with a high stable 22% Hb F level.(ABSTRACT TRUNCATED AT 250 WORDS)

UI MeSH Term Description Entries
D008297 Male Males
D002648 Child A person 6 to 12 years of age. An individual 2 to 5 years old is CHILD, PRESCHOOL. Children
D002675 Child, Preschool A child between the ages of 2 and 5. Children, Preschool,Preschool Child,Preschool Children
D005260 Female Females
D005500 Follow-Up Studies Studies in which individuals or populations are followed to assess the outcome of exposures, procedures, or effects of a characteristic, e.g., occurrence of disease. Followup Studies,Follow Up Studies,Follow-Up Study,Followup Study,Studies, Follow-Up,Studies, Followup,Study, Follow-Up,Study, Followup
D005602 France A country in western Europe bordered by the Atlantic Ocean, the English Channel, the Mediterranean Sea, and the countries of Belgium, Germany, Italy, Spain, Switzerland, the principalities of Andorra and Monaco, and by the duchy of Luxembourg. Its capital is Paris. Corsica,Saint Pierre and Miquelon,Miquelon and Saint Pierre,Miquelon and St. Pierre,St. Pierre and Miquelon
D006086 Graft vs Host Disease The clinical entity characterized by anorexia, diarrhea, loss of hair, leukopenia, thrombocytopenia, growth retardation, and eventual death brought about by the GRAFT VS HOST REACTION. Graft-Versus-Host Disease,Homologous Wasting Disease,Runt Disease,Graft-vs-Host Disease,Disease, Graft-Versus-Host,Disease, Graft-vs-Host,Disease, Homologous Wasting,Disease, Runt,Diseases, Graft-Versus-Host,Diseases, Graft-vs-Host,Graft Versus Host Disease,Graft-Versus-Host Diseases,Graft-vs-Host Diseases
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000293 Adolescent A person 13 to 18 years of age. Adolescence,Youth,Adolescents,Adolescents, Female,Adolescents, Male,Teenagers,Teens,Adolescent, Female,Adolescent, Male,Female Adolescent,Female Adolescents,Male Adolescent,Male Adolescents,Teen,Teenager,Youths
D000755 Anemia, Sickle Cell A disease characterized by chronic hemolytic anemia, episodic painful crises, and pathologic involvement of many organs. It is the clinical expression of homozygosity for hemoglobin S. Hemoglobin S Disease,HbS Disease,Sickle Cell Anemia,Sickle Cell Disease,Sickle Cell Disorders,Sickling Disorder Due to Hemoglobin S,Anemias, Sickle Cell,Cell Disease, Sickle,Cell Diseases, Sickle,Cell Disorder, Sickle,Cell Disorders, Sickle,Disease, Hemoglobin S,Hemoglobin S Diseases,Sickle Cell Anemias,Sickle Cell Diseases,Sickle Cell Disorder

Related Publications

F Bernaudin, and G Souillet, and J P Vannier, and E Plouvier, and S Lemerle, and G Michel, and P Bordigoni, and P Lutz, and J P Vernant
January 1985, The American journal of pediatric hematology/oncology,
F Bernaudin, and G Souillet, and J P Vannier, and E Plouvier, and S Lemerle, and G Michel, and P Bordigoni, and P Lutz, and J P Vernant
January 1990, Transactions of the American Clinical and Climatological Association,
F Bernaudin, and G Souillet, and J P Vannier, and E Plouvier, and S Lemerle, and G Michel, and P Bordigoni, and P Lutz, and J P Vernant
February 1994, The Journal of pediatrics,
F Bernaudin, and G Souillet, and J P Vannier, and E Plouvier, and S Lemerle, and G Michel, and P Bordigoni, and P Lutz, and J P Vernant
March 1996, Current opinion in hematology,
F Bernaudin, and G Souillet, and J P Vannier, and E Plouvier, and S Lemerle, and G Michel, and P Bordigoni, and P Lutz, and J P Vernant
February 1994, The American journal of pediatric hematology/oncology,
F Bernaudin, and G Souillet, and J P Vannier, and E Plouvier, and S Lemerle, and G Michel, and P Bordigoni, and P Lutz, and J P Vernant
February 1984, Blood,
F Bernaudin, and G Souillet, and J P Vannier, and E Plouvier, and S Lemerle, and G Michel, and P Bordigoni, and P Lutz, and J P Vernant
March 2001, Current opinion in oncology,
F Bernaudin, and G Souillet, and J P Vannier, and E Plouvier, and S Lemerle, and G Michel, and P Bordigoni, and P Lutz, and J P Vernant
January 1984, Blood,
F Bernaudin, and G Souillet, and J P Vannier, and E Plouvier, and S Lemerle, and G Michel, and P Bordigoni, and P Lutz, and J P Vernant
July 1991, Seminars in hematology,
F Bernaudin, and G Souillet, and J P Vannier, and E Plouvier, and S Lemerle, and G Michel, and P Bordigoni, and P Lutz, and J P Vernant
March 1951, Anais do Instituto de Medicina Tropical,
Copied contents to your clipboard!